SG11201913104QA - New uses of a pure 5-ht 6 receptor antagonist - Google Patents
New uses of a pure 5-ht 6 receptor antagonistInfo
- Publication number
- SG11201913104QA SG11201913104QA SG11201913104QA SG11201913104QA SG11201913104QA SG 11201913104Q A SG11201913104Q A SG 11201913104QA SG 11201913104Q A SG11201913104Q A SG 11201913104QA SG 11201913104Q A SG11201913104Q A SG 11201913104QA SG 11201913104Q A SG11201913104Q A SG 11201913104QA
- Authority
- SG
- Singapore
- Prior art keywords
- pure
- receptor antagonist
- new uses
- new
- antagonist
- Prior art date
Links
- 239000003751 serotonin 6 antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741023375 | 2017-07-03 | ||
| PCT/IB2018/054841 WO2019008484A1 (en) | 2017-07-03 | 2018-06-29 | New uses of a pure 5-ht 6 receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201913104QA true SG11201913104QA (en) | 2020-01-30 |
Family
ID=63080233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201913104QA SG11201913104QA (en) | 2017-07-03 | 2018-06-29 | New uses of a pure 5-ht 6 receptor antagonist |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210338661A1 (en) |
| EP (1) | EP3648765A1 (en) |
| JP (1) | JP6959371B2 (en) |
| KR (1) | KR102508303B1 (en) |
| CN (1) | CN110799189A (en) |
| AU (1) | AU2018297653C1 (en) |
| BR (1) | BR112019027707A2 (en) |
| CA (1) | CA3067929C (en) |
| EA (1) | EA202090127A1 (en) |
| IL (1) | IL271694A (en) |
| MA (1) | MA50018A (en) |
| MX (1) | MX2019015606A (en) |
| NZ (1) | NZ761037A (en) |
| SG (1) | SG11201913104QA (en) |
| WO (1) | WO2019008484A1 (en) |
| ZA (1) | ZA201908471B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11013564B2 (en) | 2018-01-05 | 2021-05-25 | Board Of Regents Of The University Of Nebraska | Single-arm robotic device with compact joint design and related systems and methods |
| KR20220108123A (en) | 2019-12-02 | 2022-08-02 | 수벤 라이프 사이언시스 리미티드 | Treatment of behavioral and psychological symptoms in dementia patients |
| KR20220110518A (en) | 2019-12-02 | 2022-08-08 | 수벤 라이프 사이언시스 리미티드 | Treatment of behavioral and psychological symptoms in dementia patients |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003237599B2 (en) | 2002-11-28 | 2009-06-18 | Suven Life Sciences Limited | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
| EP1581538B1 (en) * | 2002-12-18 | 2007-02-28 | Suven Life Sciences Limited | Tetracyclic 3-substituted indoles having serotonin receptor affinity |
| RU2420318C2 (en) * | 2004-09-30 | 2011-06-10 | Ф.Хоффманн-Ля Рош Аг | Compositions and methods for treating cognitive disorders |
| EP2412705B1 (en) * | 2009-03-26 | 2014-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel therapeutic agent for cognitive impairment |
| EP3043799A1 (en) * | 2013-09-09 | 2016-07-20 | Sanofi | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
| AU2014358682B2 (en) * | 2013-12-02 | 2016-10-20 | Suven Life Sciences Limited | Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate |
| CN109069449A (en) * | 2016-05-18 | 2018-12-21 | 苏文生命科学有限公司 | Pure 5-HT6The combination of receptor antagonist and nmda receptor antagonist |
| EA038087B1 (en) * | 2016-05-18 | 2021-07-05 | Сувен Лайф Сайенсиз Лимитед | Triple pharmaceutical combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist, use of said combination and a pharmaceutical composition thereof in treating cognitive disorders and method of such treatment |
| ES2879675T3 (en) * | 2016-10-03 | 2021-11-22 | Suven Life Sciences Ltd | Pharmaceutical composition of 5-HT6 antagonist |
-
2018
- 2018-06-29 JP JP2019572134A patent/JP6959371B2/en active Active
- 2018-06-29 MA MA050018A patent/MA50018A/en unknown
- 2018-06-29 WO PCT/IB2018/054841 patent/WO2019008484A1/en active Search and Examination
- 2018-06-29 BR BR112019027707-2A patent/BR112019027707A2/en active Search and Examination
- 2018-06-29 EP EP18749539.5A patent/EP3648765A1/en active Pending
- 2018-06-29 NZ NZ761037A patent/NZ761037A/en unknown
- 2018-06-29 SG SG11201913104QA patent/SG11201913104QA/en unknown
- 2018-06-29 CN CN201880043407.9A patent/CN110799189A/en active Pending
- 2018-06-29 CA CA3067929A patent/CA3067929C/en active Active
- 2018-06-29 US US16/625,313 patent/US20210338661A1/en active Pending
- 2018-06-29 MX MX2019015606A patent/MX2019015606A/en unknown
- 2018-06-29 KR KR1020207002500A patent/KR102508303B1/en active IP Right Grant
- 2018-06-29 AU AU2018297653A patent/AU2018297653C1/en active Active
- 2018-06-29 EA EA202090127A patent/EA202090127A1/en unknown
-
2019
- 2019-12-19 ZA ZA2019/08471A patent/ZA201908471B/en unknown
- 2019-12-24 IL IL271694A patent/IL271694A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3067929C (en) | 2022-09-20 |
| BR112019027707A2 (en) | 2020-08-11 |
| US20210338661A1 (en) | 2021-11-04 |
| AU2018297653A1 (en) | 2020-02-06 |
| WO2019008484A1 (en) | 2019-01-10 |
| KR102508303B1 (en) | 2023-03-09 |
| ZA201908471B (en) | 2022-06-29 |
| KR20200019747A (en) | 2020-02-24 |
| EA202090127A1 (en) | 2020-04-15 |
| AU2018297653C1 (en) | 2022-03-31 |
| MA50018A (en) | 2020-07-08 |
| JP2020525480A (en) | 2020-08-27 |
| NZ761037A (en) | 2022-10-28 |
| CN110799189A (en) | 2020-02-14 |
| IL271694A (en) | 2020-02-27 |
| EP3648765A1 (en) | 2020-05-13 |
| CA3067929A1 (en) | 2019-01-10 |
| MX2019015606A (en) | 2022-09-07 |
| JP6959371B2 (en) | 2021-11-02 |
| AU2018297653B2 (en) | 2021-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1250029A1 (en) | Dopamine d3 receptor antagonists having a bicyclo moiety | |
| IL276400A (en) | Dopamine d3 receptor antagonists compounds | |
| ZA201908471B (en) | New uses of a pure 5-ht 6 receptor antagonist | |
| EP3666772A4 (en) | Diarylthiohydantoin compound as androgen receptor antagonist | |
| IL247143B (en) | Novel use of sigma-1 receptor agonist compounds | |
| SG11201706501VA (en) | AMIDE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS | |
| EP3495363A4 (en) | Nitrogen-containing condensed ring compound having dopamine d3 receptor antagonistic effect | |
| IL262921B (en) | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors | |
| HK1258023A1 (en) | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist | |
| IL258606B (en) | Dopamine d3 receptor antagonists having a morpholine moiety | |
| ZA202000758B (en) | Fluoropiperidine compounds as pure 5-ht6 receptor antagonists | |
| EP3388423A4 (en) | Nk1 receptor antagonist | |
| IL282364A (en) | Uses of a 5-ht4 receptor agonist | |
| GB201513871D0 (en) | Bicyclo dopamine D3 receptor antagonists | |
| GB201518125D0 (en) | Dopamine D3 receptor antagonist having a bicyclo moiety | |
| GB201419433D0 (en) | Dopamine D3 receptor antagonist compounds | |
| GB201419430D0 (en) | Dopamine D3 receptor antagonist compounds |